238 related articles for article (PubMed ID: 29288357)
1. Corneal delivery of besifloxacin using rapidly dissolving polymeric microneedles.
Bhatnagar S; Saju A; Cheerla KD; Gade SK; Garg P; Venuganti VVK
Drug Deliv Transl Res; 2018 Jun; 8(3):473-483. PubMed ID: 29288357
[TBL] [Abstract][Full Text] [Related]
2. Effect of Mucoadhesive Polymeric Formulation on Corneal Permeation of Fluoroquinolones.
Gade SK; Shivshetty N; Sharma N; Bhatnagar S; Garg P; Venuganti VVK
J Ocul Pharmacol Ther; 2018 Oct; 34(8):570-578. PubMed ID: 30136888
[TBL] [Abstract][Full Text] [Related]
3. Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery.
Thakur RR; Tekko IA; Al-Shammari F; Ali AA; McCarthy H; Donnelly RF
Drug Deliv Transl Res; 2016 Dec; 6(6):800-815. PubMed ID: 27709355
[TBL] [Abstract][Full Text] [Related]
4. Study on the fabrication and characterization of tip-loaded dissolving microneedles for transdermal drug delivery.
Zhuang J; Rao F; Wu D; Huang Y; Xu H; Gao W; Zhang J; Sun J
Eur J Pharm Biopharm; 2020 Dec; 157():66-73. PubMed ID: 33059004
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Sanders ME; Moore QC; Norcross EW; Shafiee A; Marquart ME
J Ocul Pharmacol Ther; 2010 Apr; 26(2):193-8. PubMed ID: 20334537
[TBL] [Abstract][Full Text] [Related]
6. Microneedle ocular patch: fabrication, characterization, and
Roy G; Galigama RD; Thorat VS; Garg P; Venuganti VVK
Drug Dev Ind Pharm; 2020 Jul; 46(7):1114-1122. PubMed ID: 32468863
[No Abstract] [Full Text] [Related]
7. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
[TBL] [Abstract][Full Text] [Related]
8. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Sanders ME; Norcross EW; Moore QC; Shafiee A; Marquart ME
Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci.
Miller D; Chang JS; Flynn HW; Alfonso EC
J Ocul Pharmacol Ther; 2013 Apr; 29(3):339-44. PubMed ID: 23289847
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B containing microneedle ocular patch for effective treatment of fungal keratitis.
Roy G; Galigama RD; Thorat VS; Mallela LS; Roy S; Garg P; Venuganti VVK
Int J Pharm; 2019 Dec; 572():118808. PubMed ID: 31678387
[TBL] [Abstract][Full Text] [Related]
12. Poly (vinyl alcohol) microneedles: Fabrication, characterization, and application for transdermal drug delivery of doxorubicin.
Nguyen HX; Bozorg BD; Kim Y; Wieber A; Birk G; Lubda D; Banga AK
Eur J Pharm Biopharm; 2018 Aug; 129():88-103. PubMed ID: 29800617
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
14. Preparation and evaluation of novel chitosan: gelrite ocular system containing besifloxacin for topical treatment of bacterial conjunctivitis: scintigraphy, ocular irritation and retention assessment.
Imam SS; Bukhari SNA; Ali A
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):959-967. PubMed ID: 28708424
[TBL] [Abstract][Full Text] [Related]
15. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
16. Multilayered pyramidal dissolving microneedle patches with flexible pedestals for improving effective drug delivery.
Lau S; Fei J; Liu H; Chen W; Liu R
J Control Release; 2017 Nov; 265():113-119. PubMed ID: 27574991
[TBL] [Abstract][Full Text] [Related]
17. Dissolvable microneedle patch containing doxorubicin and docetaxel is effective in 4T1 xenografted breast cancer mouse model.
Bhatnagar S; Bankar NG; Kulkarni MV; Venuganti VVK
Int J Pharm; 2019 Feb; 556():263-275. PubMed ID: 30557681
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
Comstock TL; Paterno MR; Decory HH; Usner DW
Clin Drug Investig; 2010; 30(10):675-85. PubMed ID: 20629472
[TBL] [Abstract][Full Text] [Related]
19. Innovative polymeric system (IPS) for solvent-free lipophilic drug transdermal delivery via dissolving microneedles.
Dangol M; Yang H; Li CG; Lahiji SF; Kim S; Ma Y; Jung H
J Control Release; 2016 Feb; 223():118-125. PubMed ID: 26732554
[TBL] [Abstract][Full Text] [Related]
20. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
